Sturlimogene erparepvec

Oncolytic virus

Phase 2/3underway

Evidence outlook · registrational

Uveal Melanoma: registrational readout pending

No completed mid-stage readout is on record. Registrational readout expected around 2030-01.

Featured evidence outside this drug's tracked markets:NCT04336241 · Solid Tumors · Phase 1 · ungraded

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 2/3 (1)
Phase 2 (6)
Other / comorbidity
NCT07862530 · Yana Najjar
2026-12-31 – 2033-12-31 · MelanomaCutaneous Melanoma Resectable, Melanoma
What this study did
NCT07059611 · Abramson Cancer Center at Penn Medicine
2027-04-01 – 2029-11-01 · Gastric Adenocarcinoma, Esophageal Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
What this study did
NCT06623110 · Glenn J. Hanna
2025-01-01 – 2029-01-01 · High-Risk Oral Precancerous Disease
What this study did
NCT05733598 · Replimune, Inc.
2024-08-01 – 2028-07-01 · Hepatocellular Carcinoma, Biliary Tract Cancer
What this study did
NCT07218692 · City of Hope Medical Center
2026-08-11 – 2027-08-11 · Advanced Clear Cell Renal Cell Carcinoma, Advanced Renal Cell Carcinoma, Advanced Sarcomatoid Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma, Metastatic Sarcomatoid Renal Cell Carcinoma, Recurrent Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8
What this study did
NCT05733611 · Replimune, Inc.
2023-06-29 – 2025-08-18 · Refractory Metastatic Colorectal Cancer, pMMR, MSS
What this study did
Phase 1 (1)
Other / comorbidity
NCT04336241 · Replimune, Inc.
2019-10-17 – 2026-10-31 · Cancer
What this study did
Early phase / not applicable (1)
Other / comorbidity
NCT03840603 · BioMérieux
2019-09-01 – 2022-11-01 · Respiratory Tract Infections
What this study did

Competitive landscape

This drug's own stage for Uveal Melanoma: Phase 2/3. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Sturlimogene Erparepvec: this drugPhase 2/3Oncolytic virusOncolytic HSV-1 (tumour lysis and immune stimulation)not yet gradedNo reviewed efficacy summary in this indication
Tebentafusp-Tebn (KIMMTRAK)ApprovedProtein / enzyme therapeuticgp100-HLA-A*02:01 x CD3Partial signal
NCT03070392: Efficacy: Overall Survival (From randomization to the data cut off date of 13-Oct-2020; median follow-up duration was 14.1 months.): Tebentafusp 21.7 Months (95% CI 18.6 to 28.6) | Investigator's Choice 16 Months (95% CI 9.7 to 18.4)
DarovasertibPhase 3Small moleculeProtein kinase C (PKC) (inhibitor)Partial signal
NCT05987332: Primary endpoint, PFS by blinded independent central review: median 6.9 vs 3.1 months vs investigator's choice (HR 0.42; 95% CI 0.30-0.59) (IDEAYA, 2026-04-13).
RoginolisibPhase 2Small moleculePI3K-deltanot yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(5 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Sturlimogene erparepvec to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (3)
January 2027 (1)
Phase 2High-Risk Oral Precancerous DiseaseRecruiting
Est. primary completion 2027-01-01 · NCT06623110 · CT.gov ↗
What to watch
November 2027 (1)
Phase 2Gastric Adenocarcinoma, Esophageal Adenocarcinoma, Gastroesophageal Junction AdenocarcinomaNot yet recruiting
Est. primary completion 2027-11-01 · NCT07059611 · CT.gov ↗
What to watch
December 2027 (1)
Phase 2Hepatocellular Carcinoma, Biliary Tract CancerRecruiting
Est. primary completion 2027-12-01 · NCT05733598 · CT.gov ↗
What to watch
2028 (1)
February 2028 (1)
Phase 2MelanomaCutaneous Melanoma Resectable, MelanomaNot yet recruiting
Est. primary completion 2028-02-27 · NCT07862530 · CT.gov ↗
What to watch
2030 (1)
January 2030 (1)
Phase 2/3Uveal MelanomaRecruiting
Est. primary completion 2030-01 · NCT06581406 · CT.gov ↗
What to watch

See the full readout calendar ↗